Loading...
XBRU
FAGR
Market cap1.71bUSD
May 12, Last price  
21.20EUR
1D
-0.70%
1Q
9.28%
Jan 2017
118.26%
IPO
128.13%
Name

Fagron NV

Chart & Performance

D1W1MN
P/E
19.17
P/S
1.77
EPS
1.11
Div Yield, %
1.42%
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
10.28%
Revenues
872m
+14.28%
283,248,000276,971,000304,368,000354,506,000391,315,000424,056,000492,330,000547,020,000386,119,000447,056,000472,996,000421,839,000436,934,000471,679,000534,695,000555,971,000573,808,000683,881,000762,991,000871,960,000
Net income
81m
+14.18%
15,063,00012,123,00016,260,00014,900,00019,639,00022,479,00028,140,00043,906,000-32,102,00016,226,000-202,328,000-20,562,00046,658,00042,486,00055,687,00059,601,00061,004,00069,612,00070,547,00080,554,000
CFO
110m
+2.34%
34,541,00017,570,00027,100,00027,741,00039,496,00042,126,00072,147,00067,744,00063,078,000101,696,00073,311,00067,504,00084,247,00073,278,00077,175,00092,953,00078,419,000109,458,000107,379,000109,893,000
Dividend
May 21, 20240.3 EUR/sh

Profile

Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it supplies raw materials, utensils and equipment, semi-finished products, vehicles, and sterile and non-sterile compounded medicines. Further, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. It has operations in Latin America, North America, Europe, the Middle East, and Africa. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
URL
https://fagron.com/
IPO date
Oct 05, 2007
Employees
3,035
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
871,960
14.28%
762,991
11.57%
683,881
19.18%
Cost of revenue
479,603
609,644
400,018
Unusual Expense (Income)
NOPBT
392,357
153,347
283,863
NOPBT Margin
45.00%
20.10%
41.51%
Operating Taxes
23,296
13,401
17,703
Tax Rate
5.94%
8.74%
6.24%
NOPAT
369,061
139,946
266,160
Net income
80,554
14.18%
70,547
1.34%
69,612
14.11%
Dividends
(21,046)
(18,265)
(14,571)
Dividend yield
1.72%
1.51%
1.51%
Proceeds from repurchase of equity
(2,859)
1,036
453
BB yield
0.23%
-0.09%
-0.05%
Debt
Debt current
10,150
9,678
19,009
Long-term debt
420,756
398,769
423,615
Deferred revenue
1
Other long-term liabilities
6,872
5,029
6,647
Net debt
310,210
264,146
296,069
Cash flow
Cash from operating activities
109,893
107,379
109,458
CAPEX
(26,233)
(38,473)
(18,497)
Cash from investing activities
(69,743)
(44,757)
(69,269)
Cash from financing activities
(54,012)
(57,025)
13,852
FCF
276,541
156,720
219,223
Balance
Cash
115,924
137,276
125,337
Long term investments
4,772
7,025
21,218
Excess cash
77,098
106,151
112,361
Stockholders' equity
793,375
734,676
677,532
Invested Capital
821,860
733,247
663,527
ROIC
47.46%
20.04%
41.95%
ROCE
43.65%
18.23%
36.38%
EV
Common stock shares outstanding
72,937
73,000
72,886
Price
16.76
0.90%
16.61
25.17%
13.27
-10.34%
Market cap
1,222,427
0.82%
1,212,530
25.37%
967,197
-10.13%
EV
1,536,609
1,480,548
1,517,434
EBITDA
428,709
187,869
315,160
EV/EBITDA
3.58
7.88
4.81
Interest
17,438
22,979
10,620
Interest/NOPBT
4.44%
14.98%
3.74%